This project will develop a chemistry-based approach to monitoring and manipulating the immune system. If successful, it will provide a diagnostic platform of extraordinary utility as well as lead compounds for drugs to inhibit specific immune responses without general immunosuppression. We will employ microarrays comprised of thousands of peptide-like compounds called peptoids and hybridize serum samples to these arrays, resulting in the binding of thousands of proteins and several cell types to the immobilized peptoids. The hybridization pattern of interest will be visualized using an appropriate fluorescently labeled antibody, for example a labeled anti-IgG antibody will """"""""light up"""""""" the pattern of binding of all IgG antibodies. Each antibody will evince a different pattern of binding to the array based on the spectrum of affinities of that molecule for the thousands of peptoids on the array. The weighted sum of these binding signatures is expected to provide a """"""""superpattern"""""""" that should provide a sensitive readout of the population of circulating antibodies. By comparison of appropriate patients and matched control samples, we should be able to identify features in the superpatterns that are common to the disease of interest, reflecting capture of autoantibodies that are amplified in an autoimmune disease, cancer, a particular infection, etc. The same type of experiment could be done to identify disease state-associated T cells. The most informative peptoids could be used as pseudo biomarkers for diagnosis. Finally, the peptoids identified as good pseudo biomarkers for the disease state will be examined as possible therapeutic agents in various autoimmune conditions, the idea being that these peptoids may capture antibodies or T cells that are not only indicative of the disease, but may be causative as well. This approach holds out the possibility of discovering reagents capable of blocking specific immune responses without global suppression of the immune system.

National Institute of Health (NIH)
Office of The Director, National Institutes of Health (OD)
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-NDPA-G (P2))
Program Officer
Jones, Warren
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Reddy, M Muralidhar; Wilson, Rosemary; Wilson, Johnnie et al. (2011) Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 144:132-42
Kodadek, Thomas (2010) Development of antibody surrogates for the treatment of cancers and autoimmune disease. Curr Opin Chem Biol 14:721-7
Lee, Jiyong; Udugamasooriya, D Gomika; Lim, Hyun-Suk et al. (2010) Potent and selective photo-inactivation of proteins with peptoid-ruthenium conjugates. Nat Chem Biol 6:258-60
Kodadek, Thomas (2010) Synthetic receptors with antibody-like binding affinities. Curr Opin Chem Biol 14:713-20
Astle, John M; Simpson, Levi S; Huang, Yong et al. (2010) Seamless bead to microarray screening: rapid identification of the highest affinity protein ligands from large combinatorial libraries. Chem Biol 17:38-45
Cai, Di; Shames, David S; Raso, Maria Gabriela et al. (2010) Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res 70:6477-85
Gocke, Anne R; Udugamasooriya, D Gomika; Archer, Chase T et al. (2009) Isolation of antagonists of antigen-specific autoimmune T cell proliferation. Chem Biol 16:1133-9
Simpson, Levi S; Burdine, Lyle; Dutta, Amal K et al. (2009) Selective toxin sequestrants for the treatment of bacterial infections. J Am Chem Soc 131:5760-2